M801

antibody from Invitrogen Antibodies

Targeting: CXCL8 3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1

Western blot

ELISA

Antibody data

Submit

Validation data

Product number: M801 - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-8 (CXCL8) Monoclonal Antibody (3IL8-H10)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: M801 targets IL-8 in ELISA, and WB applications and shows reactivity with Human samples. The M801 immunogen is recombinant human IL-8. M801 detects IL-8 which has a predicted molecular weight of approximately 9 kDa. The M801 IL8 antibody (clone 3IL8-H10) has successfully been paired as the coating antibody in a sandwich ELISA with detection antibody M802B (biotinylated conjugate of clone I8-S2). Typical dilutions for sandwich ELISA include 1 µg/mL for coating and 0.125 - 0.25 µg/mL for detection. Antibody M801 (clone 3IL8-H10) and biotinylated antibody M802B (clone I8-S2) have successfully been used in combination with recombinant IL8 protein SIL8 in ELISA applications. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: 3IL8-H10
Vial size: 500 µg
Concentration: 1.0 mg/mL
Storage: -20°C

CXCL8 protein structure - M801 shown in red.

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Sandwich ELISA analysis of human IL-8 was performed using a Human IL-8 Colorimetric ELISA kit (Product # EH2IL8) by loading 50 µL per well of Human IL-8 Recombinant Protein (Product # SIL8) in dodecuplicate at 1000, 400, 160, 64, 25.6, and 0 pg/mL across a 3 µg/mL mouse anti-Human IL-8 (Product # M801) pre-coated plate and incubating for 1 hour at room temperature. The plate was washed, and then incubated with 50 µL per well of a biotinylated mouse anti-human IL-8 monoclonal antibody (Product # M802B) in duplicate at 0.25 µg/mL for 1 hour at room temperature. The plate was washed and incubated with 100 µL per well of Streptavidin-HRP (Product # N504) in all test wells at a 1:4,000 dilution for 30 minutes at room temperature. Detection was performed using 1-Step Ultra TMB substrate (Product # 34028) for 30 minutes at room temperature in the dark. The plate was then stopped with 0.16M sulfuric acid. Absorbances were read on a spectrophotometer at 450-550 nm.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Microparticle composition influences inflammatory cytokine production from activated monocytes. THP-1 cells ( A ) or CD14 sorted blood monocytes ( B ) were treated with control microparticles (grey bars) or PPARgamma-overexpressing microparticles (black bars) or no microparticles (white bars) for 4 hours before activation with LPS or PAM3CSK4 for 24 hours. Supernatants were collected and pro-inflammatory cytokines IL-8 (top), MCP-1 (bottom) were measured by ELISA. Dotted line represents baseline cytokine production from unactivated cells with no microparticle exposure. Mean values with standard errors represent one of at least 3 experiments. Two-way ANOVA with Tukey's multiple comparison post test was performed to determine statistical significance. * indicates (p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 9 Co-expression of progerin with Bodipy and IL-8 in HGPS differentiated SKPs. ( a ) Immunofluorescence staining for progerin and Bodipy at days 7 and 14 of adipogenesis in HGPS (HGADFN127). ( b ) Immunofluorescence staining for progerin and IL-8 at days 7 and 14 of adipogenesis in HGPS. Cells were counterstained with DAPI. ( c ) Percentage of positive nuclei expressing either progerin, Bodipy, or both (progerin/Bodipy 493/503). ( d ) Percentage of progerin-positive nuclei, IL-8-positive or progerin/IL-8-positive cells. Values are presented as mean +- SD ( n = 3), not significant (ns), ** p < 0.01, ( c , d ) unpaired t -test.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 2 FIGURE CAFs up-regulated NRP-1 expression by IL-8 in gallbladder cancer (GBC). (A) CAFs up-regulated NRP-1 expression in different GBC cell lines (GBC-SD, SGC-996 and NOZ). (B) Cytokine array cluster analysis of the exocrine cytokines in CAFs and NFs. (C) The IL-8 expression in CAFs and NFs were determined by ELISA Kit. (D) IL-8 in NFs and CAFs cells. Green: IL-8 (marked with arrow); Blue: nuclei (stained with DAPI). Scale bar: 25 mum. (E) IL-8 up-regulated NRP-1 expression in different GBC cell lines (GBC-SD, SGC-996 and NOZ). (F) IL-8 receptors inhibitor Reparixin reduced the expression of NRP-1 in GBC cell lines which up-regulated by CAFs supernatants (GBC-SD, NOZ). * P < .05 by ANOVA